false
0000882291
0000882291
2024-08-14
2024-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 14, 2024
Aethlon
Medical, Inc.
(Exact name of registrant as specified in its
charter)
Nevada |
001-37487 |
13-3632859 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
11555
Sorrento Valley Road, Suite
203
San Diego, California |
92121 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (619) 941-0360
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
AEMD |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition.
The information provided
below in “Item 7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) is
incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On August 14, 2024, Aethlon Medical, Inc.
(the “Company”) issued a press release regarding its financial results for the quarter ended June 30, 2024. A copy of that
press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
The information set forth
under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference
language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed
an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 14, 2024 |
Aethlon Medical, Inc. |
|
|
|
|
By: |
/s/ James B. Frakes |
|
Name:
|
James B. Frakes
Interim Chief Executive Officer and Chief Financial Officer
|
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/882291/000168316824005697/image_001.jpg)
Aethlon Medical
Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
Received Two Australian Ethics Committee Approvals
for a Safety, Feasibility, and Dose Finding Study of Aethlon’s Hemopurifier® in Patients with Solid Tumors Not Responding to
Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024
Achieved Significant 24% Reduction in Fiscal
First Quarter Operating Expenses Compared to the Same Period in 2023
Conference Call to be Held Today at 4:30 p.m.
ET
SAN DIEGO, August 14, 2024 -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases,
today reported financial results for its fiscal first quarter ended June 30, 2024 and provided an update on recent developments.
Company Updates
Aethlon Medical is continuing the research and
clinical development of its Hemopurifier®, a therapeutic blood filtration system designed to bind and remove harmful exosomes
and life-threatening viruses from blood and other biological fluids. These qualities of the Hemopurifier have potential applications in
oncology, where cancer associated exosomes may promote immune suppression and metastasis, in life-threatening infectious diseases, and
in organ transplantation.
As announced on August 12, 2024, the Bellberry
Human Research Ethics Committee (BHREC) granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding
clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy
treatment, such as Merck’s Keytruda® (pembrolizumab) or Bristol Myers Squibb’s Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier
Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the
Pindara Private Hospital, located in Queensland, Australia.
Earlier, on June 18, 2024, the Human Research
Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for the same safety, feasibility
and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during
anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The
approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer
Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia.
Currently, only approximately 30% of patients
who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by
tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been
designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical
studies, the Hemopurifier has been shown to reduce the number of EVs in cancer patient plasma samples.
"During the fiscal first quarter and subsequent
period, we have continued to make significant progress advancing towards our planned oncology trials in Australia and India, punctuated
by the recent approval from the Bellberry Human Research Ethics Committee (BHREC), which granted full ethics approval to the Pindara Private
Hospital and earlier from the Human Research Ethics Committee at Central Adelaide Local Health Network, in June, for a safety, feasibility
and dose-finding clinical trial of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1
monotherapy treatment,” stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical.”
“Going forward, the next steps are to receive
approval from the Research Governance Office at each hospital, which reviews indemnities and insurance. Once these approvals are obtained,
Aethlon, in concert with our Australian Contract Research Organization, ReSQ, will conduct Site Initiation Visits (SIVs), after which
patient enrollment in the trials may proceed. We expect that we will be open for enrollment in October 2024.”
Mr. Frakes continued, “We anticipate several
upcoming, potential value-creating milestones, including submission to the Ethics Committees at a third site in Australia and one in site
in India, with the expectation of possibly receiving approval from one or both of those hospitals in the September or December quarter
of 2024. After approval is granted, we expect to be able to enroll patients at those additional sites by the end of 2024.”
As a reminder, the primary endpoint of the approximate
9 to 18-patient, safety, feasibility and dose-finding trial, is safety. The trial will monitor any adverse events and clinically significant
changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals,
after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the PD-1 antibody
therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments
during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed
to decrease the concentration of EVs and if these changes in EV concentrations improve the body’s own natural ability to attack
tumor cells. These exploratory central laboratory analyses are expected to inform the design of subsequent efficacy and safety trials,
including a Premarket Approval (PMA) study required by the FDA and other regulatory agencies.
The company continues
to explore opportunities to expand the use of the Hemopurifier as a treatment for life-threatening viral infections. In vitro, it has
shown effectiveness in capturing viruses such as Zika, Lassa, MERS-CoV, cytomegalovirus, Epstein-Barr, Herpes simplex, Chikungunya, Dengue,
West Nile, smallpox-related viruses, H1N1 swine flu, H5N1 bird flu, Monkeypox, and the reconstructed 1918 Spanish flu virus. The company’s
COVID-19 trial in India remains open to accommodate any potential COVID-19 admissions to the intensive care units at the two participating
sites, Medanta Medicity Hospital and Maulana Azad Medical College. So far, one patient has been treated. The company is actively evaluating
COVID-19 admissions and potential enrollment against the ongoing costs of maintaining the trial.
Financial Results for the Fiscal First Quarter
Ended June 30, 2024
As of June 30, 2024, Aethlon Medical had a cash
balance of approximately $9.1 million.
Consolidated operating expenses for the fiscal
quarter ended June 30, 2024 were approximately $2.6 million compared to $3.4 million for the fiscal quarter ended June 30, 2023. This
decrease of approximately $800,000, or approximately 24%, in the 2024 period was due to a decrease of approximately $600,000 in general
and administrative expenses and a decrease of approximately $300,000 in professional fees partially offset by an increase in payroll and
related expenses of approximately $100,000.
The $600,000 decrease in general and administrative
expenses in the fiscal quarter ended June 30, 2024 was primarily due to a $447,000 decrease in supplies related to the purchase of raw
materials for manufacturing of the Hemopurifier and for lab supplies.
The approximate $300,000 decrease in professional
fees was primarily due to a $136,000 decrease in consulting expenses primarily related to termination of services with a contract manufacturing
organization, a $110,000 decrease in scientific consulting, and a $78,000 decrease in legal fees relating to general corporate matters.
The approximate $100,000 increase in payroll and
related was primarily due to an increase in separation expenses of approximately $300,000 related to the termination of an employee. That
increase was offset by a decrease of $111,000 in stock-based compensation and an $89,000 decrease in general and administration personnel
expense.
As a result of the factors noted above, the company’s
net loss decreased to approximately $2.6 million in the fiscal quarter ended June 30, 2024 from approximately $3.3 million in the fiscal
quarter ended June 30, 2023.
The consolidated balance sheet for June 30, 2024,
and the consolidated statements of operations for the fiscal quarters ended June 30, 2024 and 2023 follow at the end of this release.
Conference Call
Management will host a conference call today,
Wednesday, August 14, 2024, at 4:30 p.m. ET to review the company’s financial results and recent corporate developments. Following
management’s formal remarks, there will be a question and answer session.
Interested parties can register for the conference
by navigating to https://dpregister.com/sreg/10191735/fd44630e3d . Please note that registered participants will receive their dial-in
number upon registration.
Interested parties without internet access or
unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical,
Inc. conference call.
A replay of the call will be available approximately
one hour after the end of the call through September 14, 2024. The replay can be accessed via Aethlon Medical’s website or by dialing
1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is
3788019.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company
focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening
viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening
viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing
its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression
and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated
Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant
of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of
the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application
related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Additional information can be found at www.AethlonMedical.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that
involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect,"
"intend," "plan," "project," "will," "projections," "estimate," "potentially"
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties
and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements
are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors
that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable
to the Company, or at all; the Company’s ability to successfully complete development of the Hemopurifier; the Company’s ability
to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting;
the Company’s ability to achieve and realize the anticipated benefits from potential milestones; the Company’s ability to
submit applications to, and obtain approval from, the additional Ethics Committees in Australia and India, including on the timeline expected
by the Company; the Company’s ability to initiate its planned oncology clinical trials in Australia and India, including on the
timeline expected by the Company; the Company’s ability to obtain approvals from Research Governance Offices at relevant hospitals
and complete site initiation visits in a timely manner; the Company’s ability to manage and successfully complete its clinical trials,
if initiated; the Company’s ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials;
unforeseen changes in regulatory requirements; the Company’s ability to maintain its Nasdaq listing; and other potential risks.
The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ
materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission,
including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date
on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this
information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated
Balance Sheets
| |
June 30, 2024 | | |
March 31, 2024 | |
ASSETS | |
CURRENT ASSETS | |
| | | |
| | |
Cash and cash equivalents | |
$ | 9,072,379 | | |
$ | 5,441,978 | |
Deferred offering costs | |
| – | | |
| 277,827 | |
Prepaid expenses | |
| 478,058 | | |
| 505,983 | |
| |
| | | |
| | |
TOTAL CURRENT ASSETS | |
| 9,550,437 | | |
| 6,225,788 | |
| |
| | | |
| | |
Property and equipment, net | |
| 929,306 | | |
| 1,015,229 | |
Right-of-use lease asset | |
| 813,900 | | |
| 883,054 | |
Patents, net | |
| 963 | | |
| 1,100 | |
Restricted cash | |
| 87,506 | | |
| 87,506 | |
Deposits | |
| 33,305 | | |
| 33,305 | |
| |
| | | |
| | |
TOTAL ASSETS | |
$ | 11,415,417 | | |
$ | 8,245,982 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable | |
$ | 1,068,135 | | |
$ | 777,862 | |
Due to related parties | |
| 732,518 | | |
| 546,434 | |
Lease liability, current portion | |
| 296,093 | | |
| 290,565 | |
Other current liabilities | |
| 32,203 | | |
| 215,038 | |
| |
| | | |
| | |
TOTAL CURRENT LIABILITIES | |
| 2,128,949 | | |
| 1,829,899 | |
| |
| | | |
| | |
Lease liability, less current portion | |
| 573,852 | | |
| 649,751 | |
| |
| | | |
| | |
TOTAL LIABILITIES | |
| 2,702,801 | | |
| 2,479,650 | |
| |
| | | |
| | |
COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| |
| | | |
| | |
EQUITY | |
| | | |
| | |
| |
| | | |
| | |
Common stock, par value of $0.001, 60,000,000 shares authorized; 13,937,227
and 2,629,725 issued and outstanding | |
| 13,937 | | |
| 2,629 | |
Additional-paid in capital | |
| 165,844,620 | | |
| 160,337,371 | |
Accumulated other comprehensive loss | |
| (7,773 | ) | |
| (6,940 | ) |
Accumulated deficit | |
| (157,138,168 | ) | |
| (154,566,728 | ) |
| |
| | | |
| | |
TOTAL STOCKHOLDERS' EQUITY | |
| 8,712,616 | | |
| 5,766,332 | |
| |
| | | |
| | |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | |
$ | 11,415,417 | | |
$ | 8,245,982 | |
AETHLON MEDICAL, INC. AND SUBSIDIARY
Consolidated Statements
of Operations
For the three month periods ended June 30, 2024 and 2023
| |
Fiscal Year | | |
Fiscal Year | |
| |
Ended 6/30/24 | | |
Ended 6/30/23 | |
| |
| | |
| |
OPERATING COSTS AND EXPENSES | |
| | | |
| | |
Professional fees | |
$ | 614,082 | | |
$ | 976,638 | |
Payroll and related | |
| 1,254,802 | | |
| 1,123,239 | |
General and administrative | |
| 751,974 | | |
| 1,308,283 | |
Total operating expenses | |
| 2,620,858 | | |
| 3,408,160 | |
| |
| | | |
| | |
OPERATING LOSS | |
| (2,620,858 | ) | |
| (3,408,160 | ) |
| |
| | | |
| | |
OTHER EXPENSE (INCOME) | |
| | | |
| | |
Interest Income | |
| 49,418 | | |
| 125,981 | |
| |
| | | |
| | |
NET LOSS | |
$ | (2,571,440 | ) | |
$ | (3,282,179 | ) |
| |
| | | |
| | |
OTHER COMPREHENSIVE LOSS | |
| (833 | ) | |
| (994 | ) |
| |
| | | |
| | |
COMPREHENSIVE LOSS | |
$ | (2,572,273 | ) | |
$ | (3,283,173 | ) |
| |
| | | |
| | |
Basic and diluted net loss available to common stockholders per share | |
$ | (0.34 | ) | |
$ | (1.35 | ) |
| |
| | | |
| | |
Basic and diluted weighted average number of common shares outstanding | |
| 7,457,888 | | |
| 2,431,476 | |
v3.24.2.u1
Cover
|
Aug. 14, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 14, 2024
|
Entity File Number |
001-37487
|
Entity Registrant Name |
Aethlon
Medical, Inc.
|
Entity Central Index Key |
0000882291
|
Entity Tax Identification Number |
13-3632859
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
11555
Sorrento Valley Road
|
Entity Address, Address Line Two |
Suite
203
|
Entity Address, City or Town |
San Diego
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92121
|
City Area Code |
619
|
Local Phone Number |
941-0360
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.001 par value per share
|
Trading Symbol |
AEMD
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Aethlon Medical (NASDAQ:AEMD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aethlon Medical (NASDAQ:AEMD)
Historical Stock Chart
From Aug 2023 to Aug 2024